CA3149844A1 - Viral particles for use in treating synucleinopathies such as parkinson's diseases by gene therapy - Google Patents

Viral particles for use in treating synucleinopathies such as parkinson's diseases by gene therapy

Info

Publication number
CA3149844A1
CA3149844A1 CA3149844A CA3149844A CA3149844A1 CA 3149844 A1 CA3149844 A1 CA 3149844A1 CA 3149844 A CA3149844 A CA 3149844A CA 3149844 A CA3149844 A CA 3149844A CA 3149844 A1 CA3149844 A1 CA 3149844A1
Authority
CA
Canada
Prior art keywords
seq
aav
viral particle
promoter
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3149844A
Other languages
English (en)
French (fr)
Inventor
Gloria Gonzalez Aseguinolaza
Jose Luis Lanciego Perez
Ralph Michael Linden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Fundacion para la Investigacion Medica Aplicada
Centro de Investigación Biomédica en Red
Original Assignee
UCB Biopharma SRL
Fundacion para la Investigacion Medica Aplicada
Centro de Investigación Biomédica en Red
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67659024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3149844(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB Biopharma SRL, Fundacion para la Investigacion Medica Aplicada, Centro de Investigación Biomédica en Red filed Critical UCB Biopharma SRL
Publication of CA3149844A1 publication Critical patent/CA3149844A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01062—Glycosylceramidase (3.2.1.62)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
CA3149844A 2019-08-12 2020-08-06 Viral particles for use in treating synucleinopathies such as parkinson's diseases by gene therapy Pending CA3149844A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382706 2019-08-12
EP19382706.0 2019-08-12
PCT/EP2020/072087 WO2021028299A1 (en) 2019-08-12 2020-08-06 Viral particles for use in treating synucleinopathies such as parkinson's diseases by gene therapy

Publications (1)

Publication Number Publication Date
CA3149844A1 true CA3149844A1 (en) 2021-02-18

Family

ID=67659024

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3149844A Pending CA3149844A1 (en) 2019-08-12 2020-08-06 Viral particles for use in treating synucleinopathies such as parkinson's diseases by gene therapy

Country Status (18)

Country Link
US (1) US20220298528A1 (cg-RX-API-DMAC7.html)
EP (1) EP4013437A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023500011A (cg-RX-API-DMAC7.html)
KR (1) KR20220099944A (cg-RX-API-DMAC7.html)
CN (1) CN114786694A (cg-RX-API-DMAC7.html)
AR (1) AR119609A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020328827A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022002615A2 (cg-RX-API-DMAC7.html)
CA (1) CA3149844A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000292A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022001192A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP22008949A (cg-RX-API-DMAC7.html)
IL (1) IL290357A (cg-RX-API-DMAC7.html)
MX (1) MX2022001676A (cg-RX-API-DMAC7.html)
PE (1) PE20220601A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550282A1 (cg-RX-API-DMAC7.html)
TW (1) TW202120687A (cg-RX-API-DMAC7.html)
WO (1) WO2021028299A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113795575A (zh) 2019-02-04 2021-12-14 自由行疗法有限公司 多核苷酸
CA3181024A1 (en) * 2020-08-06 2022-02-10 Fundacion Para La Investigacion Medica Aplicada Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy
JP2025516136A (ja) * 2022-04-19 2025-05-27 シャンハイ ヴァイタルゲン バイオファーマ カンパニー リミテッド 神経変性疾患の治療のための組み換えaavベクター
CN121406674A (zh) * 2022-10-08 2026-01-27 凌意(杭州)生物科技有限公司 用于治疗GCase缺乏相关疾病的多核苷酸
KR20250046126A (ko) * 2023-09-22 2025-04-02 주식회사 스탠드업테라퓨티스 신규한 파킨슨 병 치료제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2985235A1 (en) * 2015-05-07 2016-11-10 Shire Human Genetic Therapies, Inc. Glucocerebrosidase gene therapy for parkinson's disease
CN111542549A (zh) * 2017-10-03 2020-08-14 普利维尔治疗公司 用于溶酶体障碍的基因疗法
WO2019068854A1 (en) * 2017-10-06 2019-04-11 Ospedale San Raffaele S.R.L. GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS

Also Published As

Publication number Publication date
AR119609A1 (es) 2021-12-29
CO2022001192A2 (es) 2022-07-19
BR112022002615A2 (pt) 2022-05-03
TW202120687A (zh) 2021-06-01
US20220298528A1 (en) 2022-09-22
PH12022550282A1 (en) 2022-11-21
KR20220099944A (ko) 2022-07-14
WO2021028299A1 (en) 2021-02-18
EP4013437A1 (en) 2022-06-22
ECSP22008949A (es) 2022-03-31
CN114786694A (zh) 2022-07-22
AU2020328827A1 (en) 2022-03-03
MX2022001676A (es) 2022-05-03
IL290357A (en) 2022-04-01
JP2023500011A (ja) 2023-01-04
PE20220601A1 (es) 2022-04-25
CL2022000292A1 (es) 2022-10-21

Similar Documents

Publication Publication Date Title
AU2015367385B2 (en) Nucleic acid constructs and gene therapy vectors for use in the treatment of Wilson disease
US20220298528A1 (en) Viral particles for use in treating synucleinopathies such as parkinson's diseases by gene therapy
US11118238B2 (en) Nucleic acid constructs and gene therapy vectors for use in the treatment of Wilson's disease and other conditions
IL278868B2 (en) Gene therapies for lysosomal disorders
US20240417434A1 (en) Nucleic acid constructs, viral vectors and viral particles
US20230365652A1 (en) Nucleic Acid Constructs, Viral Vectors and Viral Particles
EP3877000A1 (en) Codon-optimized abcb11 transgene for the treatment of progressive familial intrahepatic cholestasis type 2 (pfic2)
US20230277687A1 (en) Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy
EP4223320B1 (en) Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3)
US20240091382A1 (en) Minimal bile acid inducible promoters for gene therapy
TW202434729A (zh) 含有星狀細胞導向啟動子構築體之合成核酸及其使用方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220923

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20250619

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260121

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260323